Continuous glucose monitoring data can be reviewed, analyzed, and ultimately leveraged for diabetes treatment decision making. The Glucose Management Indicator (GMI) which determines an average A1C level based on mean continuous glucose monitoring data (Bergenstal RM, et al. 2018;41:2275-2280) was evaluated alongside time in target glucose range (TIR) during MiniMed™ 670G system use by over 3,000 real-world individuals living with diabetes. MiniMed™ 670G system data from individuals with T1D aged 14-22 years (n=291) and >22 years (n= 3174) were voluntarily uploaded from 3/17/2017 to 12/17/2018, de-identified, and analyzed if captured over the course of ≥365 days. The percentage of time in Auto Mode, TIR (70-180 mg/dL [3.9-10.0 mmol/L]) and time spent in hypoglycemia (<54 mg/dL [3.0 mmol/L]) were assessed alongside the GMI (3.31 + 0.02392 x [mean glucose in mg/dL]), 7-10 days after starting SmartGuard™ Auto Mode use. Over the analysis period, the median (min-max) of Auto Mode use was 77% (70.0-85.5%) in the >22 years cohort, and 62% (50.4-75.0%) in the younger cohort. In both cohorts, the mean TIR was above 70.0% and the time spent at <54 mg/dL stayed below 1.0% (<14min). The GMI for the older and younger cohorts was on an average 6.9% and 7.3% respectively, which is under 7.0% and 7.5%, meeting ADA recommended A1C targets for adult and pediatric age groups with diabetes, respectively. These findings indicate maintained glycemic control with concomitant Auto Mode usage and TIR, without increasing hypoglycemia, in real-world settings for individuals living with T1D and using the MiniMed™ 670G system.


S. Gopalakrishnan: Employee; Self; Medtronic. T.L. Cordero: Employee; Self; Medtronic. M. Sadeghzadeh: Employee; Self; Medtronic. M. Stone: None. P. Agrawal: Employee; Self; Medtronic MiniMed, Inc. Stock/Shareholder; Self; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at